Activity of immune checkpoint inhibition in platinum refractory germ-cell tumors

Ann Oncol. 2016 Jul;27(7):1356-60. doi: 10.1093/annonc/mdw146. Epub 2016 Mar 30.

Authors

S Zschäbitz¹, F Lasitschka², D Jäger¹, C Grüllich³

Affiliations

¹ Department of Medical Oncology, National Center for Tumor Diseases (NCT).
² Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
³ Department of Medical Oncology, National Center for Tumor Diseases (NCT) [email protected].

PMID: 27029705
DOI: 10.1093/annonc/mdw146

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use*
Cisplatin / pharmacology
Cisplatin / therapeutic use*
Drug Resistance, Neoplasm / drug effects*
Humans
Male
Neoplasms, Germ Cell and Embryonal / diagnostic imaging
Neoplasms, Germ Cell and Embryonal / drug therapy*
Nivolumab
Platinum / therapeutic use
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Testicular Neoplasms / diagnostic imaging
Testicular Neoplasms / drug therapy*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Antineoplastic Agents, Immunological
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab
Platinum
pembrolizumab
Cisplatin